News | December 17, 2010

Data Shows Covered Stent as Potentially Important Tool in AMI Therapy


December 17, 2010 – Meta analysis data delivered at the Innovations in Interventional Cardiology 2010 meeting demonstrated the low adverse cardiac events of a coronary stent merged with an embolic protection device. The MGuard, from InspireMD, is specifically designed for acute myocardial infarction (AMI) patients.

Long-term data, including two years of clinical follow-up, was presented by Dariusz Dudek, from Poland. A panel also discussed the advancement into becoming an important tool in modern AMI therapy.

The device’s embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The coronary stent provides permanent embolic protection without affecting deliverability.

It is CE Mark approved.

For more information: www.inspire-md.com


Additional Content

News | Embolic Protection Devices

April 25, 2023 — FastWave Medical, a privately-held company founded by Big Sky Biomedical partners, announces the ...

Home April 25, 2023
Home
News | Embolic Protection Devices

January 11, 2023 — In recent years, transcatheter mitral valve replacement (TMVR) treatment and technology has evolved ...

Home January 11, 2023
Home
News | Embolic Protection Devices

September 17, 2022 — Boston Scientific Corporation has announced results from the PROTECTED TAVR clinical trial ...

Home September 17, 2022
Home
News | Embolic Protection Devices

February 9, 2021 — InspireMD Inc., developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke ...

Home February 09, 2021
Home
News | Embolic Protection Devices

August 6, 2019 — Cardiovascular Systems Inc. (CSI) has acquired the Wirion Embolic Protection System and related assets ...

Home August 06, 2019
Home
Subscribe Now